André Zimerman

Head of Clinical Trials, @hospitalmoinhos 🇧🇷 | Professor, PG Cardiology, @ufrgsnoticias 🇧🇷 | Fellowship, @TIMIStudyGroup 🇺🇸 | Lipids, Trials, Cardiology

[André Zimerman @AndreZimerman]

Today, I had the honor to present PhysioSync-HF as a Late-Breaking Clinical Trial at #ESCCongress.

Key message: In HFrEF and LBBB, conduction system pacing was *inferior* to biventricular pacing for a composite of death, HF events, and LVEF change at 12 months.

[André Zimerman @AndreZimerman]

Terrific thread, thank you for highlighting @FedericaFogacci!

[Federica Fogacci @FedericaFogacci]

When TG reach ≥10 mmol/L, the question is no longer only lipid lowering. It is #pancreatitis prevention.
At #EASCongress2026, @AndreZimerman presents CORE TIMI 72a and CORE2 TIMI 72b data on #olezarsen in patients with TG ≥10 mmol/L and acute pancreatitis risk @TIMIStudyGroup

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

#EASCongress2026
@AndreZimerman presents a late breaker clinical trial exploring olezarsen for acute pancreatitins in pts w/triglycerides>10 mMol/L. As can be seen, a stark difference in favour of Olezarsen in this cohort highly exposed to risk of acute pancreatitis.

[André Zimerman @AndreZimerman]

One of my favorite projects at TIMI.

While exploratory, our findings support the concept that lowering LDL-C through PCSK9i may prevent the formation and progression of arterial aneurysms, including AAA.

Now in @CircAHA

@PrakritiGaba @marstonMD @BrianBergmark @TIMIStudyGroup

[Circulation @CircAHA]

#Research letter: Earlier initiation of the PCSK9 inhibitor Evolocumab reduced the risk of arterial aneurysm events compared with delayed initiation in an analysis of the FOURIER trial https://t.co/OaIfeZzb58

[André Zimerman @AndreZimerman]

@MargaridaPujol @JAMACardio @HeartOTXHeartMD Looks like the legend was meant for PhysioSync 🤦‍♂️

[TIMI Study Group @TIMIStudyGroup]

We are deeply saddened to have lost our founding chairman and the father of modern academic cardiology, Dr. Eugene Braunwald, who founded the TIMI Study Group in 1984, and with that vision profoundly shaped the practice of cardiovascular medicine across the world.

[Circulation @CircAHA]

#SimPub #ACC26 In CCTA substudy of Essence-TIMI 73b (RCT of olezarsen vs. placebo in patients with hypertriglyceridemia), no difference in non calcified, coronary plaque volu... @marstonMD @maciejbanach @AndreZimerman @michael_t_lu @BrianBergmark @BudoffMd https://t.co/huWruTtamz

[André Zimerman @AndreZimerman]

@drjohnm We tried our best to encompass risk stratification and LDL-C targets into a one-stop figure in the 2025 Brazilian guidelines.

While categories could be improved, IMO this is a more helpful format for quick decision-making, as is the flowchart.

See here: https://t.co/0PZ6JGZYUi

[JAMA Cardiology @JAMACardio]

In patients with #HeartFailure and #LBBB, conduction system pacing (#CSP) was inferior to biventricular pacing (#BiVP) for a composite of death, heart failure events, and LVEF change at 12 months.

https://t.co/aZwV1oICjz

[André Zimerman @AndreZimerman]

Please check out the accompanying editorial, which nicely contextualizes the apparently opposing findings from PhysioSync-HF and HeartSync-LBBP: https://t.co/3P7f31uoJH

[André Zimerman @AndreZimerman]

Proud to see PhysioSync-HF published in @JAMACardio.

In patients with HFrEF and LBBB, conduction system pacing was inferior to biventricular pacing for a composite of death, HF events, and LVEF change at 12 months.

Let us know your thoughts: https://t.co/CiKeX8ptDr

[JAMA Cardiology @JAMACardio]

Small-interfering RNA olpasiran reduced lipoprotein(a)–apolipoprotein B particles by >95% with minimal rise in non–Lp(a)-apoB, lowering total apoB concentration in patients with cardiovascular disease. https://t.co/MD55uutUJC

[André Zimerman @AndreZimerman]

@FilipeAMoura @venkmurthy @arjunmanrai I’m sure @AnupamBJena and @ChrisWorsham could pull this off… :)

[André Zimerman @AndreZimerman]

These findings suggest that, with olpasiran, apoB particles normally destined to form Lp(a) are either not secreted into circulation or more efficiently cleared, providing context for interpreting results of ongoing trials of Lp(a)-lowering agents.

Link:
https://t.co/nH2Y8Ky2em

[André Zimerman @AndreZimerman]

How do Lp(a)-lowering agents affect atherogenic lipoproteins more broadly?

In our @JAMACardio study, we show that olpasiran, an siRNA targeting apo(a), reduced Lp(a) in >95% without increasing non-Lp(a) particles.

apoB was ultimately reduced by ~18%.

@TIMIStudyGroup

[André Zimerman @AndreZimerman]

@josenalencar Great work @josenalencar. Provocative, and huge contribution to the field. Congrats.

[JAMA Cardiology @JAMACardio]

Small-interfering RNA olpasiran reduced lipoprotein(a)–apolipoprotein B particles by >95% with minimal rise in non–Lp(a)-apoB, lowering total apoB concentration in patients with cardiovascular disease.

https://t.co/8HndQN4K3S

[TIMI Study Group @TIMIStudyGroup]

Why does interference of apo(a) synthesis with #olpasiran also lead to a net reduction in apoB particles? Read more online now @JAMACardio @DrM_ODonoghue @AndreZimerman
https://t.co/kHovQ9lUTG

[André Zimerman @AndreZimerman]

I had a great discussion with @DrJMarine on the PhysioSync-HF trial, our (unexpected) findings, and what they mean for the field.

Check out our @ACCinTouch podcast episode on Spotify:
https://t.co/bh1e2MojeQ

[American College of Cardiology @ACCinTouch]

The PhysioSync-HF trial investigates conduction system pacing as a potentially more effective & affordable alternative to traditional cardiac resynchronization therapy.

Tune into #ACCEL Lite episode for more insights ➡️ https://t.co/nQDw42DMUa

@DrJMarine @AndreZimerman #CardioX

[André Zimerman @AndreZimerman]

@KostekMilan @VKutyifa We’ll have additional analyses in the primary publication and papers to follow. Agree these will be critical to better interpret our findings in the context of prior trials.

[Joseph Marine @DrJMarine]

Greatly enjoyed speaking with @AndreZimerman about his trial results reported at ESC.25. Surprisingly, CSP inferior to conventional CRT in this HFrEF population. Listen to learn more! @ACCinTouch @a_l_bailey
ACCEL Lite: PhysioSync-HF: Conduction System vs. Biventricular Pacing in Cardiac Resynchronization in HFrEF - American College of Cardiology https://t.co/L0VNvy3sLD